Ease of Use and Versatility Designed for the ICU.
Easily Switch Between CRRT Therapies
The PRISMAFLEX System is capable of delivering multiple modes of therapy without additional equipment.
CVVHDF: Continuous Veno-Venous Hemodiafiltration
CVVHD: Continuous Veno-Venous Hemodialysis
CVVH: Continuous Veno-Venous Hemofiltration
SCUF: Slow Continuous Ultrafiltration
TPE: Therapeutic Plasma Exchange
Deliver TPE With No Additional Capital Equipment
Using the PRISMAFLEX System for TPE and CRRT means one machine for multiple therapies, potentially decreasing maintenance costs.
The only extra part needed from Baxter to run TPE on the PRISMAFLEX System is the TPE2000 disposable set.
Both CRRT and TPE can be run concurrently.
 
 
   
Easy Set-up and Use
Tubing on hemofilter sets are preconnected and color-coded for easy visual setup.
All sets automatically load and self-prime.
Intuitive on-screen troubleshooting visuals are accessible during setup and therapy delivery.
Self-checks every two hours to eliminate manual monitoring and calibration of pressure sensors.
Wide Selection of Solution Options
Allow for prescription flexibility and acid-base balance using a wide range of bicarbonate buffered solutions with various ionic formulations.1,2
May help reduce preparation time, waste and potential for medication errors associated with manually mixed products.3,4
PHOXILLUM Solution offers the only FDA-approved premixed with phosphate.
 
 
 
 
 
 
Featured Presentation
CRRT in the Era of Drug Shortages
 
 
 
Want more information?
Speak with a Baxter representative or
connect with us at an event.
Acute Therapies Institute
This initiative brings together the kidney care
community to learn from industry experts and
share best practices.
 
 
 
The PRISMAFLEX Control Unit is intended for:
Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload.
Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where fluid removal of plasma components is indicated.
Rx Only. For safe and proper use of products mentioned herein refer to the appropriate Instructions for Use or Operator's Manual.

PHOXILLUM Renal Replacement Solution Indications and Important Risk Information

Indications
PHOXILLUM solution is indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. It may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.

Important Risk Information
PHOXILLUM solution can affect electrolytes and volume and may result in hyperkalemia or hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, calcium, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately. PHOXILLUM replacement solutions contain hydrogen phosphate, a weak acid that may increase the risk of metabolic acidosis. PHOXILLUM solution can effect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Monitor blood glucose levels regularly. Patients may require initiation of or modification of antidiabetic therapy or other corrective measures during treatment.

PRISMASOL Renal Replacement Solution

Indications
PRISMASOL Renal Replacement Solution is indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolytes and acid-base imbalances. PRISMASOL Solution may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances.

Important Risk Information
PRISMASOL Renal Replacement Solution is contraindicated in patients with known hypersensitivities to this product.
PRISMASOL Solution can affect electrolytes and volume and may result in hyperkalemia or   hyperphosphatemia. Monitor hemodynamic status and fluid inputs and outputs, potassium, phosphorous, other electrolytes and acid-base balance throughout the procedure. Abnormalities may be corrected by changing the formulation of replacement solution and/or dialysate, supplementation, or adjusting flow rates appropriately. The use of PRISMASOL Solutions containing dextrose can affect blood glucose levels resulting in hypo- or hyper-glycemia depending upon the dextrose content of the replacement solution. Patients may require initiation of or modification of antidiabetic therapy or other corrective measures during treatment.
 
Please see PHOXILLUM and PRISMASOL Solutions full Prescribing Information.
1 Macias, W.L., Choice of replacement fluid/dialysate anion in continuous renal replacement therapy. American Journal of Kidney Diseases, 1996; Vol. 28, No 5, Suppl. 3 (October), pp. S15-S20.
2 Druml, W. Metabolic aspects of continuous renal replacement therapies. Kidney International, 1989, Vol. 56. Hypothetical representation by Gambro of clearance levels.
3 Culley, C.M. et al., Implementing a standardized safety procedure for continuous renal replacement therapy solutions. American Journal of Health System Pharmacy, 2006; 63:756-63.
4 Barletta, J.F., Resource Utilization and Total Cost of Commercially Available versus Manually Compounded Solutions Used for Dialysate in Continuous Renal Replacement Therapy. Hospital Pharmacy, 2008; 43:29-34.